Dec 02 2020
There has been speculation about a potential role for compulsory patent licensing if a COVID-19 treatment is discovered but the supply of the treatment cannot meet the demand for treating all afflicted individuals. This article reviews the current state of compulsory patent licensing in three key patent jurisdictions: The United States, Canada, and Europe.
Full article by Abbas Kassam and Matt Norwood available only to members of ABA’s IP Section, at ABA Landslide Magazine.
The article mentioned above is for information purposes only and does not constitute legal or professional advice.
Back to blog overview
Tags: Abbas Kassam, Coronavirus, Matthew Norwood, Patents